Terlipressin Administration in Patients Undergoing Major Liver Resection

• Status: Terminated
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study investigates if the administration of terlipressin reduces complications after major liver surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Inselspital, Berne
• Treatments: Lypressin; Terlipressin

Criteria

Inclusion Criteria:

• Patients undergoing resection of 3 or more liver segments

• Minimum age of 18

• Any gender

• Written informed consent

Exclusion Criteria

• Preoperative renal failure (GFR < 50ml/min)

• Severe liver dysfunction (Child-Turcotte-Pugh grade C)

• Hyponatremia (<132mmol/l)

• Severe aortic regurgitation, severe mitral regurgitation, heart failure

• Symptomatic coronary heart disease

• Bradycardic arrhythmia (heart rate < 60/min)

• Peripheral artery occlusive disease (clinical stadium II-IV)

• Dilatative arteriopathy, history of subarachnoidal bleeding

• Decompensated arterial hypertension (Blood pressure >160/100mmHg despite intensive treatment)

• Present or suspected acute mesenteric ischemia

• Septic shock

• Pregnancy